The drug discovery startup, co-founded by research technology producer Atomwise, has pulled in $14.5m through a round led by DCVC Bio.
X-37, a US-based drug discovery company co-founded by biotech research technology producer Atomwise, has closed a $14.5m series A round led by DCVC Bio, a fund operated by venture capital firm Data Collective.
DCVC Bio was joined in the round by VC funds Alpha Intelligence Capital and Hemi Ventures.
Founded in 2018, X-37 is working on drugs to treat diseases and disorders such as autoimmune disease, cancer and excessive blood clotting.
The company will leverage Atomwise’s artificial intelligence-driven drug design…
